Global AIDS epidemic: From epidemiology to universal treatment;VIH/sida dans le monde : de l'épidémiologie au traitement universel

Revue de Medecine Interne

Volumn 29, Issue SUPPL. 3, 2008, Pages

  Anglaret, X ^a  

^a INSERM   (France)

Author keywords

Antiretroviral treatment; Epidemiology; HIV; Sub Saharan Africa

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICA; ARTICLE; CHILD; EPIDEMIC; EUROPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; INFECTION RISK; PANDEMIC; RUSSIAN FEDERATION; SIMULATION; UKRAINE; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AFRICA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIA; CHILD; DISEASE OUTBREAKS; EUROPE; HEALTH EDUCATION; HUMANS; INCIDENCE; PREVALENCE; RISK FACTORS; SOUTH AMERICA; UNITED STATES; WORLD HEALTH;

EID: 56549099089     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2008.10.002     Document Type: Article

References (29)

1. UNAIDS. 2008 Report on the global AIDS epidemic. http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp.
2. Vernazza P.L., Troiani L., Flepp M.J., Cone R.W., Schock J., Roth F., et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV cohort study. AIDS 14 (2000) 117-121
3. Becquet R., and Leroy V. Les défis soulevés par la prévention de la transmission mère-enfant du VIH en Afrique. Presse Med 36 (2007) 1947-1957
4. Goldie S.J., Yazdanpanah Y., Losina E., Weinstein M.C., Anglaret X., Walensky R.P., et al. Cost-effectiveness of HIV treatment in resource-poor settings: the case of Cote d'Ivoire. N Engl J Med 355 (2006) 1141-1153
5. Toni T., Masquelier B., Minga A., Anglaret X., Danel C., Coulibaly A., et al. HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Cote d'Ivoire: a 4-year survey, 2002-2006. AIDS Res Hum Retroviruses 23 (2007) 1155-1160
6. Bennett D., Bertagnolio S., Sutherland D., and Gilks C. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antiviral Therapy (2008) 1-13
7. Toure S., Kouadio B., Seyler C., Traore M., Dakoury-Dogbo N., Duvignac J., et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS 22 (2008) 873-882
8. Danel C., Moh R., Anzian A., Abo Y., Chenal H., Guehi C., et al. Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr 42 (2006) 29-35
9. Kabugo C., Bahendeka S., Mwebaze R., Malamba S., Katuntu D., Downing R., et al. Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: evidence of extended virologic and CD4+ cell count responses. J Acquir Immune Defic Syndr 38 (2005) 578-583
10. Nachega J.B., Hislop M., Dowdy D.W., Lo M., Omer S.B., Regensberg L., et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 43 (2006) 78-84
11. Weidle P.J., Wamai N., Solberg P., Liechty C., Sendagala S., Were W., et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 368 (2006) 1587-1594
12. Mills E.J., Nachega J.B., Bangsberg D.R., Singh S., Rachlis B., Wu P., et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 3 (2006) e438
13. WHO. WHO expert consultation on cotrimoxazole prophylaxis in HIV Infection. WHO technical report series. Reference number: WHO/HIV/2006.01. http://www.who.int/hiv/pub/meetingreports/ctx/en (site consulté le 28 octobre 2008).
14. WHO. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach. 2006 revision. http://www.who.int/hiv/pub/guidelines/WHO Adult ART Guidelines.pdf.
15. Coetzee D., Hildebrand K., Boulle A., Maartens G., Louis F., Labatala V., et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18 (2004) 887-895
16. Etard J.F., Ndiaye I., Thierry-Mieg M., Gueye N.F., Gueye P.M., Laniece I., et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20 (2006) 1181-1189
17. Ferradini L., Jeannin A., Pinoges L., Izopet J., Odhiambo D., Mankhambo L., et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367 (2006) 1335-1342
18. Stringer J.S., Zulu I., Levy J., Stringer E.M., Mwango A., Chi B.H., et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. Jama 296 (2006) 782-793
19. Badri M., Lawn S.D., and Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet 368 (2006) 1254-1259
20. Lawn S.D., Harries A.D., Anglaret X., Myer L., and Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22 (2008) 1897-1908
21. Lawn S.D., Myer L., Bekker L.G., and Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 20 (2006) 1605-1612
22. Zachariah R., Fitzgerald M., Massaquoi M., Pasulani O., Arnould L., Makombe S., et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 20 (2006) 2355-2360
23. Brinkhof M.W., Dabis F., Myer L., Bangsberg D.R., Boulle A., Nash D., et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 86 (2008) 559-567
24. Rosen S., Fox M.P., and Gill C.J. Patient retention in antiretroviral therapy programs in Sub-Saharan Africa: A systematic review. PLoS Medicine 4 (2007) 1691-1701
25. van Oosterhout J.J., Bodasing N., Kumwenda J.J., Nyirenda C., Mallewa J., Cleary P.R., et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health 10 (2005) 464-470
26. Mee P., Fielding K.L., Charalambous S., Churchyard G.J., and Grant A.D. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 22 (2008) 1971-1977
27. Messou E., Gabillard D., Moh R., Inwoley A., Sorho S., Eholie S., et al. Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults. Bull World Health Organ 86 (2008) 435-442
28. Moore D.M., Mermin J., Awor A., Yip B., Hogg R.S., and Montaner J.S. Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr 43 (2006) 436-439
29. Siegfried N., Clarke M., and Volmink J. Randomised controlled trials in Africa of HIV and AIDS: descriptive study and spatial distribution. BMJ 331 (2005) 742